Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.
A workshop to discuss anti-inflammatory approaches in the treatment of CF was held at Novartis Institutes for Biomedical Research (NIBR, Horsham, UK) in March 2008. Key opinion leaders in the field (Hugo De Jonge, Stuart Elborn, Erich Gulbins, Mike Konstan, Rick Moss, Scott Randell and Adriano Rossi), and NIBR scientists were brought together to collectively address three main aims: (i) to identify anti-inflammatory targets in CF, (ii) to evaluate the pros and cons of targeting specific cell types and (iii) to discuss model systems to profile potential therapeutic agents. The highlights of the workshop are captured in this review.
Banner
Katharine H
KH
Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK. kathy.banner@novartis.com
De Jonge
Hugo
H
Elborn
Stuart
S
Growcott
Ellena
E
Gulbins
Erich
E
Konstan
Mike
M
Moss
Rick
R
Poll
Chris
C
Randell
Scott H
SH
Rossi
Adriano G
AG
Thomas
Lorraine
L
Waltz
David
D
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D004493:Education; D004847:Epithelial Cells / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D008214:Lymphocytes / Q000378:metabolism; D008954:Models, Biological; D009504:Neutrophils / Q000378:metabolism; D012107:Research Design
D000893:Anti-Inflammatory Agents